Terra Innovatum is Accelerating Plans to Advance its Strategic Position in the Rapidly Growing Radioisotope Market by Producing Life-Saving Cancer Isotopes

Rhea-AI Summary

Terra Innovatum (NASDAQ:GSRT) announced accelerated plans to enter the medical radioisotope market with its SOLO™ micro-modular reactor. The company is developing partnerships with leading isotope producers like NorthStar, ANSTO, and BWXT Medical to expand global reach.

The global nuclear radioisotope market is projected to grow from $7 billion in 2025 to $11.68 billion by 2030. SOLO, expected to be commercially available by 2028, is designed as a precision isotope factory capable of producing multiple isotopes simultaneously, including Mo-99/Tc-99m, Iodine-131, Cobalt-60, Iridium-192, and Lutetium-177.

The microreactor aims to address current market challenges of centralized production, aging infrastructure, and supply chain vulnerabilities by enabling localized, on-demand isotope generation for hospitals and medical facilities worldwide.

Positive

• Targets fast-growing radioisotope market projected to reach $11.68B by 2030
• SOLO reactor can produce multiple isotopes simultaneously for thousands of diagnostic procedures
• Decentralized production model reduces costs, delays, and supply chain vulnerabilities
• Strategic partnerships with major isotope producers and distributors
• Versatile capability to produce both diagnostic and therapeutic isotopes

Negative

• Commercial availability not expected until 2028
• Still pending U.S. NRC licensing approval
• Faces competition from established centralized reactors and cyclotrons

Insights

Nuclear Medicine & Healthcare Technology Specialist

Terra Innovatum's SOLO microreactor could disrupt the $7B radioisotope market by decentralizing production of critical medical materials.

Terra Innovatum is accelerating its entry into the $7 billion radioisotope market with its SOLO™ micro-modular reactor technology. This strategic pivot addresses a critical healthcare infrastructure challenge: the current centralized production model for medical isotopes relies on aging nuclear reactors with frequent outages, creating global supply disruptions for life-saving diagnostic and therapeutic materials.

The market implications are substantial. Medical radioisotopes form the backbone of modern nuclear medicine, with over 10,000 hospitals worldwide dependent on these materials. Current market projections show growth from $7 billion in 2025 to $11.68 billion by 2030, representing a 67% increase. Terra Innovatum's technology could capture significant market share by addressing the supply chain vulnerability that has plagued this sector.

The SOLO microreactor's technical advantages are purpose-built for isotope production, featuring dedicated irradiation channels for multiple targets simultaneously and integrated hot cell connections. This enables production of critical isotopes including Molybdenum-99/Technetium-99m (diagnostic imaging), Lutetium-177 and Iodine-131 (cancer therapies), Cobalt-60 (sterilization), and emerging therapeutic isotopes like Actinium-225.

The business model emphasizes partnerships with established industry leaders like NorthStar, ANSTO, and Nordion. This collaboration-focused approach suggests Terra Innovatum aims to integrate into existing distribution networks rather than competing directly with incumbents.

The commercial timeline indicates SOLO is currently progressing through NRC licensing with expected commercial availability by 2028. This represents a significant development horizon before revenue generation, which investors should factor into valuation models. The positioning as both an energy innovation and healthcare technology broadens the company's potential market but also increases regulatory complexity across multiple domains.

NEW YORK and AUSTIN, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Terra Innovatum Srl (“Terra Innovatum,” or the “Company”), a developer of micro-modular nuclear reactors, and GSR III Acquisition Corp. (Nasdaq: GSRT), a publicly traded special purpose acquisition company, today announced that it has accelerated its go-to-market plans for life-saving cancer isotope production with the SOLO™ micro-modular reactor.

Terra Innovatum is developing collaborative business models and frameworks to engage with leading isotope producers and distributors such as NorthStar, ANSTO, BWXT Medical, IRE, NRG, NTP Radioisotopes, and Nordion to broaden access, strengthen partnerships, and expand global market reach.

A Micro Reactor with a Massive Impact on Global Healthcare

According to the World Nuclear Association, over 10,000 hospitals worldwide use radioisotopes in medicine¹ with reports estimating that the nuclear radioisotope market will grow annually from $7 billion in 2025 to $11.68 billion by 2030².

For decades, the global healthcare system has relied on a handful of large nuclear reactors to produce the medical isotopes essential for diagnostics, cancer therapies, and sterilization of medical equipment. This fragile, centralized model—plagued by aging infrastructure, costly logistics, and recurring shortages—has left patients waiting for critical scans and treatments.

Terra Innovatum’s SOLO microreactor is poised to change that. Compact, safe, and purpose-built for isotope production, SOLO enables localized, on-demand generation of radioisotopes—even in remote regions where conventional reactors and supply chains cannot reach.

“SOLO is not only an energy innovation, but also a healthcare breakthrough,” said Dr. Massimo Morichi, Chief Strategy Officer of Terra Innovatum, who brings four decades of experience developing advanced nuclear technologies worldwide. “By decentralizing isotope production, SOLO ensures hospitals and patients gain faster, more reliable access to the materials that modern medicine depends on.”

________________________
_{1 Radioisotopes in medicine. World Nuclear Association. (2025). https://world-nuclear.org/information-library/non-power-nuclear-applications/radioisotopes-research/radioisotopes-in-medicine
2 MordorIntel. (2025). Nuclear medicine radioisotopes market analysis: Industry report, Size & Forecast. Mordor Intelligence. https://www.mordorintelligence.com/industry-reports/global-nuclear-medicine-radioisotopes-market-industry}

Why SOLO Matters

Medical isotopes are the invisible backbone of modern healthcare. Among the most vital are:

• Molybdenum-99 (Mo-99)/Technetium-99m (Tc-99m): cornerstone of diagnostic imaging.
• Iodine-131: essential for thyroid cancer treatment.
• Cobalt-60: critical for radiotherapy and sterilization.
• Iridium-192: supports brachytherapy.
• Lutetium-177: key for precision radiotherapy.
  
  

Today, most of these isotopes come from a few centralized reactors—such as the High Flux Reactor in the Netherlands or Canada’s CANDU fleet—meaning outages or delays have worldwide consequences. While cyclotrons (large machines that produce radioisotopes) provide partial relief, their output remains limited and costly.

SOLO, currently advancing through U.S. NRC licensing and expected to be commercially available by 2028, provides a resilient, modular alternative.

A Microreactor Engineered for Isotopes

Unlike conventional reactors, SOLO is designed as a precision isotope factory:

• Features dedicated irradiation channels for multi-target insertion.
• Integrated hot cell connections for safe processing and extraction.
• Capacity to produce multiple isotopes simultaneously.
  
  

A single SOLO can generate enough Tc-99m for thousands of diagnostic procedures annually, covering the needs of a small regional hospital. Expanded multi-target operation increases flexibility, redundancy, and scalability.

Beyond Diagnostics: On-Demand Cancer Therapy

SOLO’s flexible design supports both diagnostic and therapeutic isotope production, including:

• Lutetium-177 for neuroendocrine and prostate cancer therapies.
• Iodine-131 for thyroid cancer diagnostics and treatment.
• Actinium-225 (Ac-225): an alpha-emitter for next-generation therapies.
• Iridium-192 for brachytherapy.
• Cobalt-60 for radiotherapy and sterilization.
  
  

This dual capability supports the emerging field of theranostics, where diagnosis and therapy are seamlessly integrated—revolutionizing cancer care.

A Global Game-Changer

With demand for isotopes rising worldwide, centralized supply is increasingly unsustainable. SOLO’s decentralized, portable, and multi-target approach allows deployment in hospitals, regional medical hubs, and even remote geographies across Africa, South America, Asia, and island nations.

By producing isotopes close to where they are needed, SOLO reduces delays, costs, and reliance on vulnerable supply chains. For patients, this translates into faster diagnoses, quicker treatment, and improved survival rates.

ABOUT TERRA INNOVATUM & SOLO™
Terra Innovatum's mission is to make nuclear power accessible. We deliver simple and safe micro-reactor solutions that are scalable, affordable and deployable anywhere 1 MWe at a time.

Terra Innovatum is a pioneering force in the energy sector, dedicated to delivering innovative and sustainable power solutions. Terra Innovatum plans to leverage cutting-edge nuclear technology through the SOLO™ Micro-Modular Reactor (SMR™) to provide efficient, safe, and environmentally conscious energy. With a mission to address global energy shortages, Terra Innovatum combines extensive expertise in nuclear industry design, manufacturing, and installation licensing to offer disruptive energy solutions. Committed to propelling technological advancements, Terra Innovatum and SOLO™ are dedicated to fostering prosperity and sustainability for humankind.

It is anticipated that SOLO™ will be available globally within the next three years. Conceptualized in 2018 and engineered over six years by experts in nuclear safety, licensing, innovation, and R&D, SOLO™ addresses pressing global energy demands with a market-ready solution. Built from readily available commercial off-the-shelf components, the proven licensing path for SOLO™ enables rapid deployment and minimizes supply chain risks, ensuring final cost predictability. Designed to adapt with evolving fuel options, SOLO™ supports both LEU+ and HALEU, offering a platform ready to transition to future fuel supplies.

SOLO™ will offer a wide range of versatile applications, providing CO2-free, behind-the-meter, and off-grid power solutions for data centers, mini-grids serving remote towns and villages, and large-scale industrial operations in hard-to-abate sectors like cement production, oil and gas, steel manufacturing, and mining. It also has the ability to supply heat for industrial applications and other specialized processes, including water treatment, desalination and co-generation. Thanks to its modular design, SOLO™ can easily scale to deliver up to 1GW or more of CO2-free power with a minimal footprint, making it an ideal solution for rapidly replacing fossil fuel-based thermal plants. Beyond electricity and heat generation, SOLO™ can also contribute to critical applications in the medical sector by producing radioisotopes essential for oncology research and cancer treatment.

To learn more, visit: www.terrainnovatum.com.

CONTACTS
Giordano Morichi
Partner, Chief Business Development Officer & Investor Relations
Terra Innovatum Srl
E: g.morichi@terrainnovatum.com
W: www.terrainnovatum.com

Anantha Ramamurti
President, Chief Financial Officer
GSR III Acquisition Corp
E: anantha@gsrspac.com
P: (949) 468-7434

Nicholas Hresko-Staab
Vice President
Investor & Media Relations
Alliance Advisors IR
E: TerraIR@allianceadvisors.com

IMPORTANT INFORMATION FOR SHAREHOLDERS
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or constitute a solicitation of any vote or approval.

PARTICIPANTS IN THE SOLICITATION
Each of the Registrant Parties, and their respective directors and executive officers, may be considered participants in the solicitation of proxies with respect to the potential transaction described in this communication under the rules of the SEC. Information about the directors and executive officers of GSRT is set forth in GSRT’s filings with the SEC. Information regarding other persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders in connection with the potential transaction and a description of their direct and indirect interests will be set forth in the Registration Statement (and will be included in the proxy statement/prospectus) and other relevant documents when they are filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

FORWARD LOOKING STATEMENTS
The statements contained in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding our expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on GSRT and the other Registrant Parties. There can be no assurance that future developments affecting GSRT and the other Registrant Parties will be those that we have anticipated. These forward-looking statements speak only as of the date this press release is delivered and involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreements with respect to the Business Combination; (2) the outcome of any legal proceedings that may be instituted against GSRT, any of the Registrant Parties, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of GSRT or the SEC’s declaration of the effectiveness of the Registration Statement or to satisfy other conditions to closing; (4) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (5) the ability of Pubco to meet stock exchange listing standards following the consummation of the Business Combination; (6) the risk that the Business Combination disrupts current plans and operations of Terra Innovatum as a result of the announcement and consummation of the Business Combination; (7) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (8) costs related to the Business Combination, including the reorganization described in the business combination agreement; (9) changes in applicable laws or regulations; (10) the possibility that the Registrant Parties or the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) the amount of redemption requests made by GSRT shareholders and (12) other risk factors described herein as well as the risk factors and uncertainties described in the Form S-4 and GSRT’s other filings with the SEC, as well as any further risks and uncertainties to be contained in the proxy statement/prospectus filed after the date hereof. In addition, there may be additional risks that neither GSRT nor any of the other Registrant Parties presently know, or that GSRT or the other Registrant Parties currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward- looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made.

None of GSRT, the other Registrant Parties, or any of their respective affiliates, officers, employees or agents, makes any representation or warranty, either express or implied, in relation to the fairness, reasonableness, adequacy, accuracy, completeness or reliability of the information, statements or opinions, whichever their source, contained in this press release or any oral information provided in connection herewith, or any data it generates and accept no responsibility, obligation or liability (whether direct or indirect, in contract, tort or otherwise) in relation to any of such information. GSRT, the other Registrant Parties and their respective affiliates, officers, employees and agents further expressly disclaim any and all liability relating to or resulting from the use of this press release and any errors therein or omissions therefrom. Further, the information contained herein is preliminary, is provided for discussion purposes only, is only a summary of key information, is not complete and is subject to change without notice.

In addition, the information contained in this press release is provided as of the date hereof and may change, and neither GSRT nor the other Registrant Parties undertakes any obligation to update or revise any forward- looking statements, whether as a result of new information, inaccuracies, future events or otherwise, except as may be required under applicable securities laws.

A photo accompanying this release is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b2dca78d-29bd-46e5-8b4b-a0e5c094ac41

FAQ

What is Terra Innovatum's SOLO reactor and when will it be available?

SOLO is a micro-modular reactor designed for medical isotope production, featuring dedicated irradiation channels and integrated hot cell connections. It is expected to be commercially available by 2028, pending NRC licensing.

How large is the radioisotope market that GSRT is targeting?

The nuclear radioisotope market is projected to grow from $7 billion in 2025 to $11.68 billion by 2030, with over 10,000 hospitals worldwide using radioisotopes in medicine.

What types of medical isotopes can Terra Innovatum's SOLO reactor produce?

SOLO can produce multiple isotopes simultaneously, including Molybdenum-99/Technetium-99m for diagnostics, Iodine-131 for thyroid cancer, Cobalt-60 for radiotherapy, Iridium-192 for brachytherapy, and Lutetium-177 for precision radiotherapy.

Who are Terra Innovatum's potential partners in the radioisotope market?

The company is developing collaborations with leading isotope producers and distributors including NorthStar, ANSTO, BWXT Medical, IRE, NRG, NTP Radioisotopes, and Nordion.

What advantages does GSRT's SOLO reactor offer over traditional isotope production?

SOLO offers decentralized, on-demand isotope production closer to hospitals, reducing delays, costs, and supply chain vulnerabilities. A single unit can produce enough Tc-99m for thousands of diagnostic procedures annually.